{"id":23490,"date":"2023-01-20T08:00:00","date_gmt":"2023-01-20T08:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/press-releases\/ipsen-presente-les-donnees-de-la-phase-iii-napoli-3-sur-onivyde-demontrant-des-resultats-positifs-en-matiere-de-survie-chez-les-patients-non-precedemment-traites-atteints-dun-adenocarc\/"},"modified":"2024-07-22T11:44:04","modified_gmt":"2024-07-22T09:44:04","slug":"ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","title":{"rendered":"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0"},"content":{"rendered":"\n<p><strong>PARIS, FRANCE,<\/strong>&nbsp;le 20&nbsp;janvier&nbsp;2023 \u2014 Ipsen (Euronext&nbsp;: IPN&nbsp;; ADR&nbsp;: IPSEY) a annonc\u00e9 aujourd\u2019hui des r\u00e9sultats positifs dans le cadre de son essai pivotal de Phase&nbsp;III, nomm\u00e9 NAPOLI&nbsp;3, \u00e9valuant un traitement exp\u00e9rimental avec Onivyde<sup>\u00ae<\/sup>&nbsp;(injection d\u2019irinot\u00e9can liposomal), un inhibiteur liposomal de la topoisom\u00e9rase \u00e0 circulation longue, chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un mPDAC. Dans le cadre d\u2019une session de pr\u00e9sentation d\u2019abstracts partag\u00e9s pour la premi\u00e8re fois (LBA661) \u00e0 l\u2019occasion de l\u2019\u00e9dition 2023 du symposium sur les cancers gastro-intestinaux de l\u2019American Society of Clinical Oncology (ASCO GI), les donn\u00e9es de l\u2019essai NAPOLI 3 sur le nouveau sch\u00e9ma th\u00e9rapeutique NALIRIFOX (irinotecan liposomal 50 mg\/m<sup>2<\/sup>&nbsp;+ 5-FU 2400 mg\/m<sup>2<\/sup>&nbsp;+ leucovorine 400 mg\/m<sup>2<\/sup>&nbsp;+ oxaliplatine 60 mg\/m<sup>2<\/sup>) ont d\u00e9montr\u00e9 une am\u00e9lioration de l\u2019OS et de la PFS par rapport au nab-paclitaxel en association avec la gemcitabine.<sup>1<\/sup>&nbsp;Sur une p\u00e9riode de suivi m\u00e9diane de 16,1 mois, le sch\u00e9ma th\u00e9rapeutique exp\u00e9rimental d\u2019Onivyde a atteint son crit\u00e8re d\u2019\u00e9valuation principal, d\u00e9montrant une am\u00e9lioration statistiquement significative de OS\u00e0 11,1 mois, par rapport \u00e0 9,2 mois chez les patients trait\u00e9s avec le nab-paclitaxel et la gemcitabine (HR 0,83 [IC 95 % : 0,70\u20130,99] ; p=0,04).<sup>1\u2020<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"template":"","categories":[1233,3560],"tags":[],"class_list":["post-23490","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-pressrelease-fr","category-oncology-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-22T09:44:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0\",\"datePublished\":\"2023-01-20T08:00:00+00:00\",\"dateModified\":\"2024-07-22T09:44:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\"},\"wordCount\":263,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Oncologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\",\"name\":\"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\",\"datePublished\":\"2023-01-20T08:00:00+00:00\",\"dateModified\":\"2024-07-22T09:44:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","og_site_name":"Global","article_modified_time":"2024-07-22T09:44:04+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/"},"author":{"name":"","@id":""},"headline":"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0","datePublished":"2023-01-20T08:00:00+00:00","dateModified":"2024-07-22T09:44:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/"},"wordCount":263,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","articleSection":["Communiqu\u00e9 de presse","Oncologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","name":"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","datePublished":"2023-01-20T08:00:00+00:00","dateModified":"2024-07-22T09:44:04+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen pr\u00e9sente les donn\u00e9es de la phase III NAPOLI 3 sur Onivyde\u00ae, d\u00e9montrant des r\u00e9sultats positifs en mati\u00e8re de survie chez les patients non pr\u00e9c\u00e9demment trait\u00e9s atteints d\u2019un ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique (mPDAC), \u00e0"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/23490"}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/23490\/revisions"}],"predecessor-version":[{"id":62240,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/23490\/revisions\/62240"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/27874"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=23490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=23490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=23490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}